Oncolytics Biotech (ONCY) Assets Average (2009 - 2025)

Oncolytics Biotech (ONCY) has 17 years of Assets Average data on file, last reported at $9.3 million in Q4 2025.

• On a quarterly basis, Assets Average fell 42.54% year-over-year to $9.3 million in Q4 2025; TTM through Dec 2025 was $9.3 million, a 42.54% decrease from a year earlier, with the FY2025 full-year figure at $10.5 million, down 50.22% from the prior year.
• Assets Average for Q4 2025 stood at $9.3 million, down from $12.7 million in the prior quarter.
• Over the last five years, Assets Average for ONCY reached as high as $44.3 million in Q2 2021 and fell as low as $9.3 million in Q4 2025.
• Historically, Assets Average has averaged $27.1 million across 5 years, with a median of $27.9 million in 2022.
• Across the five-year window, Assets Average jumped 39.86% in 2021 and tumbled 48.75% in 2024, its largest moves.
• Year by year, Assets Average stood at $39.1 million in 2021, then fell by 26.61% to $28.7 million in 2022, then advanced by 9.62% to $31.4 million in 2023, then tumbled by 48.75% to $16.1 million in 2024, then sank by 42.54% to $9.3 million in 2025.
• Per Business Quant data, the three most recent Assets Average figures were $9.3 million in Q4 2025, $12.7 million in Q3 2025, and $14.1 million in Q2 2025.